Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: A review

Michelle A. Grenier, Joanne Fioravanti, Susie C. Truesdell, Alan M. Mendelsohn, Roger P. Vermilion, Steven E Lipshultz

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies. Copyright (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)91-111
Number of pages21
JournalProgress in Pediatric Cardiology
Volume12
Issue number1
DOIs
StatePublished - Dec 12 2000
Externally publishedYes

Fingerprint

Enzyme Therapy
Ventricular Dysfunction
Angiotensin-Converting Enzyme Inhibitors
Safety
Therapeutics
Pharmaceutical Preparations
Randomized Controlled Trials
Heart Failure
Pharmacokinetics

Keywords

  • ACE inhibition
  • Afterload reduction
  • Congenital heart disease
  • Congestive heart failure
  • Pediatric
  • Ventricular dysfunction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Grenier, M. A., Fioravanti, J., Truesdell, S. C., Mendelsohn, A. M., Vermilion, R. P., & Lipshultz, S. E. (2000). Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: A review. Progress in Pediatric Cardiology, 12(1), 91-111. https://doi.org/10.1016/S1058-9813(00)00061-8

Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents : A review. / Grenier, Michelle A.; Fioravanti, Joanne; Truesdell, Susie C.; Mendelsohn, Alan M.; Vermilion, Roger P.; Lipshultz, Steven E.

In: Progress in Pediatric Cardiology, Vol. 12, No. 1, 12.12.2000, p. 91-111.

Research output: Contribution to journalArticle

Grenier, Michelle A. ; Fioravanti, Joanne ; Truesdell, Susie C. ; Mendelsohn, Alan M. ; Vermilion, Roger P. ; Lipshultz, Steven E. / Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents : A review. In: Progress in Pediatric Cardiology. 2000 ; Vol. 12, No. 1. pp. 91-111.
@article{eb25a059a8ce46b0b50b7598ccf32dee,
title = "Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: A review",
abstract = "Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies. Copyright (C) 2000 Elsevier Science Ireland Ltd.",
keywords = "ACE inhibition, Afterload reduction, Congenital heart disease, Congestive heart failure, Pediatric, Ventricular dysfunction",
author = "Grenier, {Michelle A.} and Joanne Fioravanti and Truesdell, {Susie C.} and Mendelsohn, {Alan M.} and Vermilion, {Roger P.} and Lipshultz, {Steven E}",
year = "2000",
month = "12",
day = "12",
doi = "10.1016/S1058-9813(00)00061-8",
language = "English",
volume = "12",
pages = "91--111",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents

T2 - A review

AU - Grenier, Michelle A.

AU - Fioravanti, Joanne

AU - Truesdell, Susie C.

AU - Mendelsohn, Alan M.

AU - Vermilion, Roger P.

AU - Lipshultz, Steven E

PY - 2000/12/12

Y1 - 2000/12/12

N2 - Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies. Copyright (C) 2000 Elsevier Science Ireland Ltd.

AB - Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies. Copyright (C) 2000 Elsevier Science Ireland Ltd.

KW - ACE inhibition

KW - Afterload reduction

KW - Congenital heart disease

KW - Congestive heart failure

KW - Pediatric

KW - Ventricular dysfunction

UR - http://www.scopus.com/inward/record.url?scp=0033646134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033646134&partnerID=8YFLogxK

U2 - 10.1016/S1058-9813(00)00061-8

DO - 10.1016/S1058-9813(00)00061-8

M3 - Article

AN - SCOPUS:0033646134

VL - 12

SP - 91

EP - 111

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

IS - 1

ER -